Postrenal transplant renopulmonary zygomycosis with vascular aneurysms responded to surgical treatment and salvage therapy with posaconazole after failure to respond to liposomal amphotericin
نویسندگان
چکیده
BACKGROUND Zygomycosis is a difficult to treat and frequently fatal infection affecting immunocompromised and (rarely) immunocompetent patients. It requires a multifaceted approach involving elimination of predisposing factors, surgical debridement, and antifungal therapy. CASE REPORT We report the case of a postrenal transplant patient who developed disseminated zygomycosis with vascular aneurysms after receiving empirical voriconazole treatment for presumed pulmonary fungal infection in addition to immunosuppression and methylprednisolone pulses for presumed graft rejection, as renal biopsy was declined. Initially, liposomal amphotericin therapy in combination with surgical intervention failed. Addition of posaconazole as salvage therapy improved the patient outcome. He received total of 6 weeks of AmBisome and 12 weeks of posaconazole. CONCLUSIONS Zygomycosis is a difficult to treat infection. Management includes surgical debridement and antifungal therapy, namely liposomal amphotericin. However, in cases where treatment with liposomal amphotericin along with surgical intervention fails, posaconazole can be given as a salvage therapy. Duration of antifungal treatment should be determined on an individual basis.
منابع مشابه
Treatment of zygomycosis: current and new options.
Zygomycosis is a frequently lethal invasive infection in high-risk patients such as the immunocompromised [especially haematopoietic stem cell transplant (HSCT) recipients] and patients with type 2 diabetes mellitus. However, zygomycosis has also been reported in individuals without known risk factors. The causative fungi are members of the order Mucorales and individual species within this gro...
متن کاملCurrent experience in treating invasive zygomycosis with posaconazole.
The treatment of zygomycosis has two cornerstones, namely, surgery and antifungal drugs. In many patients, both need to be applied to achieve treatment success; without treatment, the mortality rate of zygomycosis approaches 100%. Because treatment options are limited, no well-designed randomized clinical trial has been conducted and data are predominantly derived from compassionate-use program...
متن کاملIsavuconazole as salvage therapy for mucormycosis
Mucormycosis carries a high mortality rate with few therapeutic options available. We describe a man with pulmonary/splenic mucormycosis complicating hypoplastic myelodysplastic syndrome on a background of chronic kidney disease, who achieved a complete response with salvage isavuconazole therapy following intolerance of consecutive courses of liposomal amphotericin and posaconazole therapy.
متن کاملPosaconazole mono- or combination therapy for treatment of murine zygomycosis.
We compared the efficacy of combination posaconazole-liposomal amphotericin B (LAmB) therapy to monotherapy with either drug in diabetic ketoacidotic or neutropenic mice with disseminated zygomycosis caused by Rhizopus oryzae. Combination therapy was no better than LAmB alone, and posaconazole monotherapy did not improve survival or reduce fungal burden versus placebo.
متن کاملSuccessful treatment of pulmonary zygomycosis in two transplant recipients with liposomal amphotericin B and partial surgical resection followed by posaconazole.
David T. Cooke, Francis D. Pagani, Daniel R. Kaul, Kenneth R. Cooke, Christine L. Lau and James Riddell IV Division of Cardiothoracic Surgery, University of California, Davis Medical Center, Davis, CA, USA, Section of Cardiac Surgery, University of Michigan Medical Center, Ann Arbor, MI, USA, Division of Infectious Diseases, University of Michigan Medical Center, Ann Arbor, MI, USA, Department ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 13 شماره
صفحات -
تاریخ انتشار 2012